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This	 is	 a	 joint	 position	 statement	 of	 the	 British	 Society	 of	 Echocardiography,	 the	
British	Heart	Valve	Society	and	the	Society	for	Endocrinology	on	the	role	of	echocar‐








be	avoided	 if	 there	are	no	associated	pathological	 changes	 in	 leaflet	 thickness,	
restriction	 or	 retraction.	 Note	 must	 be	 taken	 that	 even	 where	 morphological	
change	in	leaflet	structure	and	function	may	be	suspected,	grading	is	semi‐quan‐







phy	 should	 then	be	performed	at	5	years	 after	 starting	 cabergoline	 in	patients	
taking	a	total	weekly	dose	less	than	or	equal	to	2	mg.	If	there	has	been	no	change	
on	the	5‐year	scan,	repeat	echocardiography	could	continue	at	5‐yearly	intervals.	









predominantly	 in	 PD,	 cabergoline	 is	 used	more	 commonly	 in	 the	




exposing	patients	 to	 the	 risks	of	hypopituitarism.4	Cabergoline	 is	
generally	 the	 agent	 of	 choice	 because	 alternatives,	 such	 as	 bro‐
mocriptine,	require	multiple	daily	doses	and	have	a	less	favourable	
side	effect	profile.	The	use	of	cabergoline	in	PD	and	hyperprolac‐
tinaemia	 differs	 considerably.	Cabergoline	 is	 used	 in	PD	patients	
over	a	shorter	period	(months)	at	much	higher	dose	(typically	3	mg	




hyperprolactinaemia	 are	more	 limited.	 As	 a	 result	 of	 the	 studies	
documenting	an	 increased	 risk	of	valulopathy	 in	PD	patients,	 the	
Medicines	 and	 Healthcare	 products	 Regulatory	 Agency	 (MHRA)	
recommended	 that	 physicians	 in	 the	 United	 Kingdom	 should	 re‐
quest	 baseline	 echocardiography	 to	 exclude	 valvular	 heart	 dis‐
ease	 in	 all	 patients	 before	 starting	 cabergoline	or	 bromocriptine,	
followed	by	a	second	echocardiogram	performed	3‐6	months	after	
commencement	 and	 then	 at	 6‐12‐month	 intervals	while	 continu‐
ing	 on	 the	medication.	 It	 was	 also	 recommended	 that	 treatment	
be	 stopped	 if	 echocardiography	 showed	 worsening	 or	 new	 val‐
vular	 restriction,	 thickening	 or	 regurgitation.	 In	 the	 intervening	
years,	 much	 echocardiographic	 data	 from	 cabergoline‐treated	













pharmacologically	 and	mechanistically	 plausible.	 Like	 other	 ergot‐
based	 drugs	 (eg,	 methysergide	 and	 the	 weight	 loss	 drugs	 fenflu‐
ramine	 and	 dexfenfluramine),	 cabergoline	 binds	 to	 the	 serotonin	
receptor	 subtype	 2B	 (5‐HT2B)	 located	 on	 heart	 valves.	 Activation	
of	 these	 receptors	 induces	 valvular	 interstitial	 cell	 mitogenesis	
and	proliferation,	which	 in	 turn	modifies	 the	quantity	 and	quality	
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stiff,	leading	most	commonly	to	valvular	regurgitation	(Figure	1A,B).	



















now	 used	 in	 echocardiography,	 but	 over‐estimates	 leaflet	 thick‐
ness	compared	to	fundamental	imaging.	Finally,	most	studies	within	
the	 prolactinoma	 literature	 only	 reported	 on	 the	 prevalence	 of	
any	 valvular	 lesion	 as	detected	by	echocardiography,	without	dis‐
tinguishing	 cabergoline‐associated	 valvulopathy	 from	 coincidental	
abnormalities	that	may	often	be	found	in	patients	in	the	UK	of	simi‐
lar	age	to	those	studied.9
3  | CURRENT E VIDENCE
Following	publication	of	the	adverse	effects	of	DA	agonists	at	high	
dose	 in	PD,	 several	 groups	published	 single	 institution,	 cross‐sec‐
tional	 case‐control	 studies	 investigating	 the	 link	 between	 chronic	
DA	therapy	at	low	dose	in	hyperprolactinaemia	and	the	presence	of	
valvular	abnormalities	(Table	1).10‐23	These	were	all	limited	by	small	
size.	 Moreover,	 the	 control	 groups	 in	 each	 study	 contained	 only	
healthy	 individuals	 or	 those	 referred	 for	 other	 cardiac	 symptoms,	
eg	 palpitations,	 who	were	 then	 found	 to	 have	 normal	 echocardi‐
ography,	rather	than	untreated	patients	with	hyperprolactinaemia.	
One	 study	 in	 50	 patients	 found	 an	 increase	 in	 the	 prevalence	 of	
moderate	(27/50;	54%)	but	not	of	mild	tricuspid	regurgitation	(TR)	
among	 those	 treated	 with	 cabergoline	 at	 a	 median	 dose	 280	mg	


















(mo) ± SD Summary
Bogazzi	(2008) 100	(21) 100	(16) 41	±	13 279	±	301 67	±	39 No	effect
Boguszewski	(2012) 51	(27) 59	(27) 42.3	±	13.5 239	±	243 38	±	21 ↑	MV	tenting 
↑	Mild	TR	(7.8%	vs	0%)
↑	Mild	PR	(no	statistics	presented)
Colao	(2008) 50	(12) 50	(12) 36.5	±	10.5 414	±	390 81	±	37 ↑	Mod	TR	(54%	vs	18%)
No	other	difference	in	VD
Cordoba	Soriano	(2013) 8	(25) 11	(34) 38.8	±	10.4 158	(median) 46 No	effect
Elenkova	2012 103	(20) 102	(21) 38.6	±	9.93 174	(no	SD) 47	+	286 ↑	Subclinical	fibrosis	(40	vs	23%)
No	other	difference	in	VD
Halperin	(2012) 15	(40) 58	(10) No	data 523	(median) No	data No	effect
Herring	(2009) 50	(60) 50	(60) 51.2	±	15.5 443	±	375 79	±	42 No	effect
Kars	(2008) 47	(28) 78	(26) 46	±	13 363	±	377 62	±	32 ↑	Mild	TR	(41%	vs	26%)
↑	AV	calcification
Lancellotti	(2008) 102	(28) 51	(37) 51	(median) 184	±	105 79	(median) ↑	MV	tenting
No	other	
difference	in	VD
Nacthigall	(2010) 100	(48) 100	(48) 44	±	13 253	±	520 48	±	40 No	effect
Tan	(2010) 72	(26) 72	(28) 36	(median) 126	(median) 53	(median) No	effect
Vallette	(2008) 70	(47) 70	(47) 44	±	13 282	±	271 55	±	22 No	effect
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cumulative	dose	363	mg;	mean	treatment	duration	60	months),	mild	
tricuspid	regurgitation	was	found	more	often	(32/78,	41%)	among	
those	 taking	DA	 agonists	 than	 in	 controls	 (20/78,	 26%),	 although	








patients	 (mean	 cumulative	 cabergoline	 dose	 204	mg;	mean	 treat‐
ment	duration	79	months),13	 there	was	an	 increase	 in	mitral	valve	
tenting	 area	 but	 no	 difference	 in	 leaflet	 thickness	 and	 no	 change	
in	any	other	valves.	 In	103	patients	 (mean	cumulative	cabergoline	
dose	174	mg;	mean	 treatment	duration	46	months),17	 there	was	a	






Finally,	 a	 large	 multi‐centre	 cross‐sectional	 study	 based	 in	 the	
United	Kingdom	of	747	patients	taking	DA	agonists	(median	caber‐





tiple	 testing	 in	 small	 groups	 and	 lack	 of	 standardised	 assessment	
of	valve	morphology.	There	are	isolated	case	reports	of	restrictive	
valve	disease	after	cabergoline	but	these	have	either	been	in	cases	
treated	with	high	dose8,25	or	in	patients	with	co‐morbidity,26 and in 
one	case	developing	bowel	obstruction	after	diagnosis	of	dopamine	
agonist	 valvulopathy	without	 exclusion	of	 co‐existing	neuroendo‐
crine tumour.27
In	 addition	 to	 the	 cross‐sectional,	 case‐control	 studies,	 there	
have	 been	 three	 studies	with	 serial	 follow‐up	 (Table	 2).	 The	 first,	
small,	 single‐centre	 study	 examined	 45	 patients	 receiving	 cab‐
ergoline	 for	 prolactinoma	 (mean	 cabergoline	 dose	 401	mg)	 with	






The	 third	 study	 followed	 100	 subjects	 for	 a	median	 interval	 62.5	













































































































































































































































































































the	 fact	 that	 long‐term,	detailed	 studies	of	 the	 size	 sufficient	 to	
exclude	an	effect	would	be	costly	to	perform	and	require	consid‐
erable	 expertise	 to	 ensure	 consistent,	 reliable	 and	 quantitative	
echocardiographic	 assessment.	 It	 is	 important	 to	note	 that	 in	 all	
studies	 performed,	 bromocriptine	 has	 not	 been	 implicated	 with	
any	valvular	abnormalities.
Alternative	imaging	modalities,	for	example	cardiovascular	mag‐
netic	 resonance	 imaging,	do	not	provide	adequate	 spatial	 or	 tem‐





caused	 by/associated	 with	 restoration	 of	 physiological	 oestrogen	
secretion.	The	expectation	that	existing	clinical	networks	could	pro‐
duce	accurate,	large	volume	data	by	applying	current	MHRA	guide‐
lines	 on	 surveillance	 by	 echocardiography	 also	 appears	 unlikely,	
since	adherence	 to	current	 recommendations	 is	poor.	 In	a	 service	
evaluation	performed	by	NHS	Highland	(North),	only	2/45	patients	
started	 on	 a	 DA	 agonist	 had	 echocardiography	 prior	 to	 starting	
therapy.33






ited	 professionals.35	 In	 each	 case,	 a	 standard	 transthoracic	 study	
should	be	performed	following	minimum	standards.36	In	addition	to	
this,	 however,	 careful	 attention	 should	be	 taken	 to	perform	 semi‐
quantitative	 assessment	of	 valve	 structure	 and	 function	 to	detect	









ment.38	Moreover,	 this	 incorporates	assessment	of	all	 four	cardiac	







Given	 that	 one	 of	 the	 major	 difficulties	 with	 the	 existing	 lit‐
erature	 is	 the	 separation	of	 valve	disease	due	 to	DA	agonist	 ther‐
apy	from	pre‐existing	changes	 in	valve	structure	and	function,	 it	 is	
recommended	 that	all	patients	 starting	DA	agonist	 therapy	should	
undergo	a	transthoracic	echocardiogram	before	drug	therapy	is	com‐
menced	(Table	4).	An	increase	in	valve	score	may	then	be	interpreted	





 Normal = 0 Mild = 1 Moderate = 2 Severe = 3
Leaflet	thickening 0 + ++ +++






Stenosis 0 Mild Moderate Severe
Regurgitation 0 Mild Moderate Severe
RV	dimension 0 >42	mm RV	=	LV RV	forming	the	
LV	apex
RV	function 0 ↓ ↓↓ ↓↓↓
Adapted	from	Bhattacharya	et	al.33
TA B L E  3  Scoring	system	for	patients	
receiving	dopamine	agonist	therapy









performing	a	 transthoracic	echocardiogram	before	drug	 therapy	 is	
commenced	may	be	unnecessary	and	that	doing	an	echocardiogram	








Given	 the	worst‐case	 scenario	 for	 potential	 progression	 based	
on	the	largest	cohort	with	serial	follow‐up,5	it	is	recommended	that	
repeat	 transthoracic	 echocardiography	 should	 be	 performed	 at	
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